Tariq Chukir

Within a year of discontinuing GLP-1s, more than half of patients with overweight/obesity or T2DM regained weight, with the greatest regain occurring in those who initially lost the most weight. @nyuendocrine shines at #OW2025

@abdarabi Thank you, Dr. Arabi!

@TChukir Congratulations, nice study

Many ppl with hypothyroidism attribute inability to lose excess wt to hypothyroidism. Our data suggest wt and body composition changes in response to lira are comparable in those with or w/o hypothyroidism. journals.plos.org/plosone/articl…

🚨 Real-World GLP-1 Data: Vanderbilt Obesity Clinic Study (n=2,306) Clinical trials showed 15–21% weight loss with semaglutide & tirzepatide. But how do patients actually fare in practice? - - - Key Findings: 📊 Median treatment duration: 10.7 months (50% discontinued by 12 months) 💉 Only 23% reached semaglutide 2.4 mg, 28% reached tirzepatide 15 mg ⚖️ Weight loss for those who continued treatment: • 6 months: –9.4% • 12 months: –14.4% 🏥 13.6% had medication-related ER visits (mostly GI side effects) Context: This was not a typical setting—patients had multidisciplinary support and NO-COST medication access through employer insurance bundles. Reality Check: ✅ With the right care model, real-world outcomes can approach RCTs ❌ Most patients never reach target doses ❌ Half stop treatment within a year 👉 The gap between “can work” and “does work” remains large. Sustained success appears tied to comprehensive care models that most patients can’t easily access. 🔗…ubs.pericles-prod.literatumonline.com/doi/10.1111/do…

@BevTchangMD Hi Bev, the difference between the 2 studies may be explained by the inclusion of functional impairment. It does not seem like functional impairment was included in Shen et al's paper.

I've been trying to sort out how 2 high quality epidemiology studies applied the Lancet Commission clinical #obesity definition and concluded with vastly different prevalences: 9.7% vs. 39.1% Shen et al examined NHANES 2017-2020 👉pubmed.ncbi.nlm.nih.gov/40660751/ - 9.7% clinical obesity prevalence - Body fat % data available only from 2017-2018 - Used waist circumference as other adiposity measure - Did not use "BMI <30 but had two or more other measures of excess adiposity" to qualify for "excess adiposity" Yao et al @JackieYaoMD @MichaelJBlaha examined All of Us Data 2017-2022 👉 thelancet.com/journals/landi… - 39.1% clinical obesity prevalence - Used waist circumference, waist to hip ratio, and waist to height ratio as other adiposity measures - Adjusted for sex and age distribution - Included "fair" or "poor" on survey responses as poor physical functioning Bonus: A third recent publication of 56 countries 👉 pmc.ncbi.nlm.nih.gov/articles/PMC12… found "The prevalence of clinical obesity ranged between 0% and 29%" using the Lancet definition 🧐 On its own, the Commission is an academic exercise, but its application into the real world has enormous implications for policy & #publichealth. For example, the NHANES study found that downgrading the epidemic would disproportionately affect minority groups, reducing the Mexican American prevalence from 50% to just 5% 🤔 Is it time for a clarification sequel? @TheLancetEndo @FRubinoMD

✨ Meet Dr. Tariq Chukir, @TChukir - Advisory Board Member for AACE MENA 2025! With a focus on diabetes innovation and practical care strategies, Dr. Chukir helps shape a program built for impact. 🔗Register: pro.aace.com/events/mena #AACEMENA25

Spanish court finds ex-football chief Luis Rubiales guilty of sexual assault for kissing player Jenni Hermoso without consent after the 2023 Women’s World Cup Final. Read here: aje.io/3vwiiu

Fantastic conference! @TChukir @MWeintraubMD

We’re excited to announce that #TacklingObesity2025 is SCOPE accredited for 3.5 points, contributing to the internationally recognized SCOPE certification in obesity! 🌟 If you haven’t registered yet, don’t miss out on this dynamic event where leading experts will share the latest strategies in weight management, covering innovative treatments and effective lifestyle interventions. ⏳ Registration closes in one week! Don’t miss your chance—reserve your spot today: bit.ly/4gMiYFb #ObesityManagement #SCOPEAccreditation #WeightManagement #CPD #ObesityCare #MedicalEducation #TacklingObesity2025 @WorldObesity @RobertoSimonsMD @WCMQatar @BevTchangMD

WCM-Q hosts second alumni-run healthcare conference @WCMQatar @UPCCqa @tchukir @mahrukhrizvi_MD @AlJerdi @stellabared @ReshmaBholah @DialaSteitieh @NimraDad @TArayssi @Sadeer_AlKindi @munjidalharthy @wcmq_alumni qatar-weill.cornell.edu/media-center/n…

Welcome to the second "Updates in Primary Care: Specialist-Led Case-Based Discussions Highlighting the Latest Evidence and Best Clinical Practices" conference, hosted by and featuring WCM-Q Alumni that aims to explore the present and future of primary care. We start the day with opening Remarks from Dr. Thurayya Arayssi, Vice Dean for Academic and Curricular Affairs, and Dr. Mahrukh S. Rizvi, Co-Director of @UPCCqa and Assistant Professor of Clinical Medicine at @WCMQatar.

Next up, we’re excited to feature Dr. Chukir @TChukir , Assistant Professor of Medicine at @WCMQatar and an @wcmq_alumni , presenting an insightful update on type 2 diabetes. This lecture will cover the burden of type 2 diabetes in Qatar, approaches to screening and diagnosis, and management strategies with a focus on the latest pharmacotherapies. Stay tuned for this informative session! #WCMQAlumConference #PrimaryCareUpdates #ClinicalBestPractices #SpecialistLedCases #HealthcareUpdates #healthcareprofessionals #GPs #Primarycaredoctors #medicine #continuingmedicaleducation

@MichaelAlbertMD 😂😂 I was asked this question yesterday during a talk. My response was “LV mass is not a clinical outcome that I typically look for or know how to interpret its clinical significance”

Oh no! Tirzepatide reduces your heart size! 😱 🤣 jacc.org/doi/10.1016/j.…

I am delighted to have had the opportunity to serve as both a speaker and an advisory board member at the AACE MENA conference in Dubai. It was an honor to present on the impact of muscle changes in obesity and weight loss, and testosterone misuse in men.

📣In-depth symposia are lighting up the AACE MENA Annual Conference 2024! With leading experts sharing their insights and sparking meaningful conversations, each session is a chance to broaden your understanding. Join us to be part of these engaging discussions, or follow along for today’s highlights! Didn’t register online? Stop by the onsite registration desk to join in! 🔗View the program: medgress-media.s3.amazonaws.com/doc/AACE/AACE2… @SarahNadeemMD @Tchukir @alfutaisia @ASZ44444 @egan_am @sfeirjad @Beshyah2024 @DrSusanSamson1 @TaheriShahrad #AACEMENA24 #DiabetesCare #BoneHealth #VitaminD #PituitaryDisorders #AdrenalHealth #ThyroidAwareness #ClinicalEndocrinology #EndocrineDisorders #HormoneHealth #endotwitter #endocrinology #diabetes

📣Get ready to be part of the in-depth Obesity Symposium at the AACE MENA Annual Conference! Join top experts as they share their expertise across various critical topics. This is a unique opportunity to connect with industry leaders, expand your knowledge, and take your career to the next level. Reserve your spot today and engage with the voices shaping tomorrow’s care! 📚 AACE MENA Annual Conference 🗓️ Dates: November 22 - 24, 2024 📍 Venue: Intercontinental Dubai Festival City 🔗 Secure your seat now: pro.aace.com/events/2024/me… @SarahNadeemMD @TaheriShahrad @Tchukir @alfutaisia @ASZ44444 @egan_am @sfeirjad @Beshyah2024 #AACEMENA24 #DiabetesCare #BoneHealth #VitaminD #PituitaryDisorders #AdrenalHealth #ThyroidAwareness #ClinicalEndocrinology #EndocrineDisorders #HormoneHealth #endotwitter #endocrinology #diabetes

Join us on Nov 22-24 in Dubai. I will be discussing changes to muscles in obesity and weight loss.

@BevTchangMD @Medscape “Ask if they have third-party confirmation of potency, stability, and sterility testing of the final product.” Which third party do you trust to confirm potency stability and sterility? Doubt Novo or Lilly are willing to do it 😂

The conversation around compounded #Ozempic should evolve. So I wrote a checklist for people seeking compounded peptides for because sharing information isn't enough. We must #EducateToEmpower medscape.com/viewarticle/ch… @Medscape #obesity #weightmanagement

@EricTopol No doubt resistance training is beneficial. However, I doubt the 6w difference observed at 4 years between HRT and Control is clinically significant in this group of physically active elderly (avg 10k steps per day witb BMI of 25).

Resistance training for 1 year in older adults had enduring benefits for years later, results from a randomized trial bmjopensem.bmj.com/content/10/2/e…